Introduction. Small bowel neuroendocrine tumours (NETs) are the most common type of gastrointestinal neuroendocrine tumours. The incidence and prevalence of these tumours are on the rise. The aims of this study were to determine prognostic clinicopathological features and whether the ENETS TNM staging system predicts prognosis and also. Method. Clinical data was collected retrospectively from 138 patients with histologically proven small bowel NETs managed at King’s College Hospital. Histology was reviewed and small bowels tumours, were staged according to the ENETS TNM staging system. Results. Median age was 65 years (range 29–87). The 5-year survival was 79.5% and the 10-year survival was 48.5%. Resection of the primary tumour was associated with improved survival (120 versus 56 months, ). On multivariate analysis prognostic factors were primary tumour resection and not having a carcinoid heart disease. TNM staging significantly separated survival of stage 2 and stage 3 from stage 4 NETs. Conclusion. Small bowel primary tumour resection and not having carcinoid heart disease are prognostic factors. The ENETS TNM staging and grading system appears to be of prognostic relevance to small bowel NETs. 1. Introduction Neuroendocrine tumours of the small bowel are the most common type of malignant neoplasm in the small intestine, accounting for 35% of small intestinal cancers [1, 2]. Small bowel neuroendocrine tumours (NETs) are the most common type of gastrointestinal neuroendocrine tumours [3]. Small bowel NETs comprise around 38% of gastroenteropancreatic NETs and 21% of all NETs. The incidence and prevalence of these tumours are on the rise, as demonstrated in the Surveillance Epidemiology and End Results (SEER) data and the population-based study in Norway [2, 4]. A threefold increase in incidence has been demonstrated in the USA between 1973 and 2002 [5]. The reported incidence of small bowel NETs is 1/100 000 population [6]. The majority of these tumours do not cause carcinoid syndrome, often presenting late with metastatic disease. Patients with non-hormone secreting tumours often present with vague symptoms, including intermittent abdominal pain or weight loss. A number of patients are identified coincidentally. Approximately 40% of patients with metastatic disease at presentation have functionally active tumours leading to the development of carcinoid syndrome [7–10]. Small bowel NETs were generally thought to be indolent tumours; however, their behaviour is more heterogeneous, and consequently a staging and grading system has been introduced by
References
[1]
I. Hatzaras, J. A. Palesty, F. Abir et al., “Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry,” Archives of Surgery, vol. 142, no. 3, pp. 229–235, 2007.
[2]
I. M. Modlin, M. C. Champaneria, A. K. C. Chan, and M. Kidd, “A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress,” American Journal of Gastroenterology, vol. 102, no. 7, pp. 1464–1473, 2007.
[3]
I. M. Modlin, K. Oberg, D. C. Chung et al., “Gastroenteropancreatic neuroendocrine tumours,” The Lancet Oncology, vol. 9, no. 1, pp. 61–72, 2008.
[4]
O. Hauso, B. I. Gustafsson, M. Kidd et al., “Neuroendocrine tumor epidemiology: contrasting Norway and North America,” Cancer, vol. 113, no. 10, pp. 2655–2664, 2008.
[5]
I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003.
[6]
J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008.
[7]
J. K. Ramage, A. H. G. Davies, J. Ardill et al., “Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours,” Gut, vol. 54, no. 4, pp. iv1–iv16, 2005.
[8]
R. Srirajaskanthan, D. Shanmugabavan, and J. K. Ramage, “Carcinoid syndrome,” The British Medical Journal, vol. 341, Article ID c3941, 2010.
[9]
O. Nilsson, L. K？lby, B. W？ngberg et al., “Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours,” British Journal of Cancer, vol. 77, no. 4, pp. 632–637, 1998.
[10]
I. Norheim, K. Oberg, and E. Theodorsson-Norheim, “Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival,” Annals of Surgery, vol. 206, no. 2, pp. 115–125, 1987.
[11]
G. Rindi, G. Kl？ppel, A. Couvelard et al., “TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 451, no. 4, pp. 757–762, 2007.
[12]
D. S. Bergestuen, L. Aabakken, K. Holm, M. Vatn, and E. Thiis-Evensen, “Small intestinal neuroendocrine tumors: prognostic factors and survival,” Scandinavian Journal of Gastroenterology, vol. 44, no. 9, pp. 1084–1091, 2009.
[13]
H. Jann, S. Roll, A. Couvelard et al., “Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome,” Cancer, vol. 117, no. 15, pp. 3332–3341, 2011.
[14]
A. Ahmed, G. Turner, B. King et al., “Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 885–894, 2009.
[15]
T. Curran, S. Tulin-Silver, K. Patel, et al., “Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors,” Pancreas, vol. 40, no. 8, pp. 1253–1257, 2011.
[16]
J. Strosberg, N. Gardner, and L. Kvols, “Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut,” Neuroendocrinology, vol. 89, no. 4, pp. 471–476, 2009.
[17]
G. Capurso, M. Rinzivillo, R. Bettini, L. Boninsegna, G. D. Fave, and M. Falconi, “Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases,” The British Journal of Surgery, vol. 99, no. 11, pp. 1480–1486, 2012.
[18]
J. K. Ramage, A. Ahmed, J. Ardill, et al., “Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs),” Gut, vol. 61, no. 1, pp. 6–32, 2012.
[19]
U. F. Pape, H. Jann, J. Müller-Nordhorn et al., “Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors,” Cancer, vol. 113, no. 2, pp. 256–265, 2008.
[20]
A. P. Burke, R. M. Thomas, A. M. Elsayed, and L. H. Sobin, “Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases,” Cancer, vol. 79, no. 6, pp. 1086–1093, 1997.
[21]
G. Rindi, W. W. de Herder, D. O'Toole, and B. Wiedenmann, “Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it,” Neuroendocrinology, vol. 84, no. 3, pp. 155–157, 2007.
[22]
A. D. Amarapurkar, A. Davies, J. K. Ramage, A. J. Stangou, D. G. D. Wight, and B. C. Portmann, “Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 2, pp. 139–143, 2003.
[23]
G. Rindi, C. Capella, and E. Solcia, “Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract,” Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 13–21, 2000.
[24]
O. Norlen, P. Stalberg, K. Oberg, et al., “Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center,” World Journal of Surgery, vol. 36, no. 6, pp. 1419–1431, 2012.
[25]
S. Bhattacharyya, J. Davar, G. Dreyfus, and M. E. Caplin, “Carcinoid heart disease,” Circulation, vol. 116, no. 24, pp. 2860–2865, 2007.
[26]
D. S. Diaco, H. Hajarizadeh, C. R. Mueller, W. S. Fletcher, R. F. Pommier, and E. A. Woltering, “Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization,” The American Journal of Surgery, vol. 169, no. 5, pp. 523–528, 1995.
[27]
C. Durante, H. Boukheris, C. Dromain et al., “Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 585–597, 2009.
[28]
K. Landerholm, N. Zar, R. E. Andersson, S. E. Falkmer, and J. Jrhult, “Survival and prognostic factors in patients with small bowel carcinoid tumour,” British Journal of Surgery, vol. 98, no. 11, pp. 1617–1624, 2011.
[29]
P. Hellman, T. Lundstr？m, U. ？hrvall et al., “Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases,” World Journal of Surgery, vol. 26, no. 8, pp. 991–997, 2002.
[30]
D. A. Osborne, E. E. Zervos, J. Strosberg et al., “Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors,” Annals of Surgical Oncology, vol. 13, no. 4, pp. 572–581, 2006.
[31]
J. M. Sarmiento, G. Heywood, J. Rubin, D. M. Ilstrup, D. M. Nagorney, and F. G. Que, “Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival,” Journal of the American College of Surgeons, vol. 197, no. 1, pp. 29–37, 2003.
[32]
R. Srirajaskanthan, C. Toumpanakis, T. Meyer, and M. E. Caplin, “Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 11, pp. 1143–1154, 2009.
[33]
A. Saxena, T. C. Chua, J. Zhao, and D. L. Morris, “Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery,” Journal of Surgical Oncology, vol. 105, no. 4, pp. 342–350, 2012.
[34]
R. C. Le, C. Lombard-Bohas, C. Delmas, et al., “Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study,” Digestive and Liver Disease, vol. 43, no. 10, pp. 828–833, 2011.
